JNJ Sees Strong Growth Ahead in High-Growth MedTech Markets
Johnson & Johnson (JNJ) is focused on high-growth MedTech markets, innovation, and portfolio shifts, which has led to strong growth projections. According to a recent presentation at the Wells Fargo 21st Annual Healthcare Conference Audio Transcript on September 9, 2026, MedTech is expected to experience high-end growth driven by a shift into cardiovascular, surgery, and vision. This growth is attributed to robust innovation and a new operating model.
Despite facing competitive and geopolitical headwinds, confidence remains high for JNJ's future prospects, with major contributions anticipated from the OTTAVA product and portfolio optimization. The company's ability to adapt and innovate has positioned it well for continued success in the MedTech industry.